Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : WR, LB and Friends. NO HYPESTERS OR SCAMMERS -- Ignore unavailable to you. Want to Upgrade?

To: amadeus who wrote (7453)	4/15/1999 12:41:00 PM
From: Mr. Fortune	Read Replies (1) \| Respond to of 13776

(BSNS WIRE) Steroidogenesis Inhibitors Receives Final Payment for Licens Steroidogenesis Inhibitors Receives Final Payment for Licensing ANTICORT to Altachem-Pharma, Canada Health Editors/Medical Writers & Columnists LAS VEGAS--(BW HealthWire)--April 15, 1999-- Altachem to Commence Clinical Study With ANTICORT(TM) Steroidogenesis Inhibitors International (OTCBB:STGI) today announced that it has received $50,000 from Altachem-Pharma, (Alberta Stock Exchange: AAF) representing the last installment on the $300,000 licensing fees for ANTICORT(TM) in Canada. Altachem-Pharma announced they have received approval from the Health Protection Bureau (HPB), the Canadian equivalent of the U.S. FDA, and will begin a Phase 1 clinical study of ANTICORT in HIV positive patients receiving anti-HIV treatment. The study in Canada is the third testing of Anticort following clinical studies in the U.S. and Romania in HIV positive children. STGI is a pharmaceutical R&D Corporation, engaged in the development of anticortisol drugs to be used in diseases/conditions associated with elevated levels of the immunosuppressive hormone cortisol. STGI's flagship anticortisol drug, ANTICORT, has been approved by the FDA to be clinically tested in an HIV population - a condition often associated with "high cortisol" that is apparently playing a major role in the destruction of the immune system as encountered in HIV+ and AIDS. This release may include "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable it can give no assurance that such expectations will prove correct. This is neither an offer to buy or sell a security. For informational purposes only, from sources deemed to be reliable. For more information visit our World Wide Web page at www.anticort.com. --30--emb/ny* CONTACT: STEROIDOGENESIS PERFORMANCE STRATEGIES Janet Greeson, Ph.D. Richard L. Brown/Chuck Jordan (702) 735-7001 (303) 471-5943 H.L. LANZET INC. Herbert Lanzet/DeeDee Lanzet (212) 687-0061 KEYWORD: NEVADA INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com * end of story *